Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The evolving relationship between sponsors and contract research organisations
If the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at ICON, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.
In this podcast and article Jeff James, EVP Alliance Management, offers his perspective on what it takes to be a trusted partner to sponsors in the clinical development industry. -
R&D outsourcing trends roundtable
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to this article on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
-
Decentralised, hybrid or traditional: Choosing the best option for your clinical trial
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
-
Pharma’s digital transformation – How to best incorporate wearables amid an evolving landscape
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
-
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
Moving from on-site" to agile: The changing dynamic in study management"
Pharmafocus (pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
-
Developing enhanced digital content to increase physician engagement
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange. Experts from ICON's Medical Communications team discuss how they are using enhanced media fit for the digital age.
-
Innovation in oncology drug development: A focus on patient benefits
An article by ICON's Dr. Brian Huber that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
Role of data in revolutionising the CRO industry
In a wide-ranging interview with PharmaBoardroom, ICON CIO, Tom O’Leary highlights the role of data in revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes.
